Your browser doesn't support javascript.
loading
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.
Smyth, Lillian M; Tamura, Kenji; Oliveira, Mafalda; Ciruelos, Eva M; Mayer, Ingrid A; Sablin, Marie-Paule; Biganzoli, Laura; Ambrose, Helen J; Ashton, Jack; Barnicle, Alan; Cashell, Des D; Corcoran, Claire; de Bruin, Elza C; Foxley, Andrew; Hauser, Joana; Lindemann, Justin P O; Maudsley, Rhiannon; McEwen, Robert; Moschetta, Michele; Pass, Martin; Rowlands, Vicky; Schiavon, Gaia; Banerji, Udai; Scaltriti, Maurizio; Taylor, Barry S; Chandarlapaty, Sarat; Baselga, José; Hyman, David M.
Afiliación
  • Smyth LM; Memorial Sloan Kettering Cancer Center, New York, New York. lilsmyth@svhg.ie.
  • Tamura K; National Cancer Center Hospital, Tokyo, Japan.
  • Oliveira M; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Ciruelos EM; Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Mayer IA; Vanderbilt Breast Center, Nashville, Tennessee.
  • Sablin MP; Institut Curie, Paris, France.
  • Biganzoli L; Breast Centre, Oncology Department, Hospital of Prato, Prato, Italy.
  • Ambrose HJ; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.
  • Ashton J; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.
  • Barnicle A; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.
  • Cashell DD; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.
  • Corcoran C; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.
  • de Bruin EC; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.
  • Foxley A; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.
  • Hauser J; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.
  • Lindemann JPO; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.
  • Maudsley R; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.
  • McEwen R; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.
  • Moschetta M; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.
  • Pass M; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.
  • Rowlands V; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.
  • Schiavon G; R&D Oncology, AstraZeneca, Cambridge, United Kingdom.
  • Banerji U; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Scaltriti M; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Taylor BS; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Chandarlapaty S; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Baselga J; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Hyman DM; Memorial Sloan Kettering Cancer Center, New York, New York.
Clin Cancer Res ; 26(15): 3947-3957, 2020 08 01.
Article en En | MEDLINE | ID: mdl-32312891
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Pirimidinas / Pirroles / Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogénicas c-akt / Fulvestrant Tipo de estudio: Clinical_trials Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Pirimidinas / Pirroles / Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogénicas c-akt / Fulvestrant Tipo de estudio: Clinical_trials Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article